These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17048708)

  • 1. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
    McCluskie MJ; Krieg AM
    Curr Top Microbiol Immunol; 2006; 311():155-78. PubMed ID: 17048708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
    Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
    Front Immunol; 2019; 10():179. PubMed ID: 30800129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
    Vollmer J
    Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
    Shima F; Uto T; Akagi T; Akashi M
    Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG DNA in the prevention and treatment of infections.
    Dalpke A; Zimmermann S; Heeg K
    BioDrugs; 2002; 16(6):419-31. PubMed ID: 12463765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
    Krieg AM
    Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
    Mutwiri G
    Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could DNA-reactive B lymphocytes be activated through HIV-1 DNA-stimulation involving BCR/TLR-9 pathway to yield antibodies targeting viral DNA?
    Norelli S
    Med Hypotheses; 2014 Dec; 83(6):659-63. PubMed ID: 25441838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9-based immunotherapy for the treatment of allergic diseases.
    Farrokhi S; Abbasirad N; Movahed A; Khazaei HA; Pishjoo M; Rezaei N
    Immunotherapy; 2017 Mar; 9(4):339-346. PubMed ID: 28303762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG motifs to modulate innate and adaptive immune responses.
    Vollmer J
    Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune effects and mechanisms of action of CpG motifs.
    Krieg AM
    Vaccine; 2000 Nov; 19(6):618-22. PubMed ID: 11090712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
    Jurk M; Vollmer J
    BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes.
    Harris TH; Mansfield JM; Paulnock DM
    Infect Immun; 2007 May; 75(5):2366-73. PubMed ID: 17339353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG Oligonucleotides as Vaccine Adjuvants.
    Kayraklioglu N; Horuluoglu B; Klinman DM
    Methods Mol Biol; 2021; 2197():51-85. PubMed ID: 32827132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
    J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
    Harandi AM; Holmgren J
    Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.